Corporate Alliance Board
National Stroke Association's mission to reduce the incidence and impact of stroke is enabled by the generous support of our Corporate Alliance Board (CAB), an elite group of industry partners with a mutual interest in stroke awareness and prevention.
Through Corporate Alliance sponsorship and grants, National Stroke Association develops educational programs about all aspects of stroke for the general public, medical professionals, and those touched personally by stroke.
National Stroke Association thanks our CAB members for their dedication to National Stroke Association's mission.
We invite you to join National Stroke Association in our efforts to reduce the incidence and impact of stroke by becoming a member of our Corporate Alliance Board. Distinct levels of sponsorship allow you to select a commitment that is consistent with your goals and resources.
For more information about becoming a CAB partner, please contact any of the following:
PRESIDENT LEVEL
|
|
|
| Boehringer Ingelheim Pharmaceuticals, Inc. discovers, develops and markets innovative and unique medications for the treatment of respiratory, cardiovascular, immunological and central nervous system diseases. BIPI is the maker of Aggrenox (aspirin and extended-release dipyridamole), approved in 1999 as an antiplatelet agent for the treatment of stroke and TIA. |
 |
|
|
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Sanofi-Synthelabo is a major global research-based pharmaceutical group with 32,500 employees in more than 100 countries. The company is headquartered in Paris and listed in Paris (Euronext : SAN) and in New York (NYSE : SNY). With consolidated sales of EUR 7.4 billion in 2002, Sanofi-Synthelabo ranks 7th in Europe and among the world's top 20 pharmaceutical companies. With an R&D portfolio of 52 compounds in development, Sanofi-Synthelabo is focused on a core group of four therapeutic areas: cardiovascular disease and thrombosis; diseases of the central nervous system; internal medicine; and oncology.
|
|
 |
|
|
Pfizer Inc is committed to helping people improve their health by discovering and developing medicines, as well as informing consumers and health care providers about our medicines and the medical conditions they treat. Through multiple initiatives, Pfizer aims to ensure access to treatments and educate, empower and motivate consumers to take the necessary steps to lead longer, healthier, happier lives. For more information about Pfizer's patient assistance programs, visit http://www.pfizerhelpfulanswers.com/.
|
|
 | back to the top
EXECUTIVE LEVEL |
| |
|
|
Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 16,000 employees and revenue of $5.6 billion in 2004. For more than 25 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The Company's products help physicians and other medical professionals improve their patients' quality of life by providing alternatives to surgery.
|
 |
back to the top
|
|
|
| EKR Therapeutics is a specialty pharmaceutical company focused on identifying, fostering and targeting the growth of novel acute-care hospital products to improve outcomes and patient quality of life. Products include: Cardene® I.V. (nicardipine hydrochloride), Retavase® (reteplase recombinant), DepoDur® (morphine sulfate extended-release liposomal injection), and Gelclair® (bioadherent oral gel). For additional information visit www.ekrtx.com. |
 |
|
|
GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceuticals is dedicated to detecting disease earlier and tailoring treatment for individual patients.
|
|
|
|
For over a decade, Genentech has been committed to advancing the treatment of stroke. In 1995, the company's t-PA, Activase® (Alteplase) was approved for reducing disability and improving recovery following acute ischemic stroke. Now, more than 60,000 eligible stroke patients have been treated. Genentech also supports numerous educational programs for healthcare professionals caring for stroke patients. For information on these resources please contact 1-88-TX-STROKE or visit http://www.activase.com/.
|
 |
|
|
|
Medtronic is the global leader in medical technology alleviating pain, restoring health and extending life for millions of people around the world. The company’s product and therapy portfolio includes intrathecal therapy for the management of severe spasticity associated with multiple sclerosis, cerebral palsy, stroke, brain injury, or spinal cord injury. For more information please visit http://www.medtronic.com/ or http://www.yourlifeafterstroke.com/
|
 |
|
|
back to the top |
